• About us
  • Privacy Policy
  • Contact us
Neo Science Hub
ADVERTISEMENT
  • Home
  • e-Mag Archives
  • e-Learning
  • Categories
    • Healthcare & Medicine
    • Pharmaceutical & Chemical
    • Automobiles
    • Blogs
      • Anil Trigunayat
      • BOOKmarked
      • Chadha’s Corner
      • Cyber Gyan
      • Raul Over
      • Taste of Tradition
        • Dr. G. V. Purnachand
      • Vantage
    • Business Hub
    • Engineering
    • Innovations
    • Life Sciences
    • Space Technology
  • PhotoSynthesis
  • Subscribe Now
  • Contact us
  • Log In
No Result
View All Result
  • Home
  • e-Mag Archives
  • e-Learning
  • Categories
    • Healthcare & Medicine
    • Pharmaceutical & Chemical
    • Automobiles
    • Blogs
      • Anil Trigunayat
      • BOOKmarked
      • Chadha’s Corner
      • Cyber Gyan
      • Raul Over
      • Taste of Tradition
        • Dr. G. V. Purnachand
      • Vantage
    • Business Hub
    • Engineering
    • Innovations
    • Life Sciences
    • Space Technology
  • PhotoSynthesis
  • Subscribe Now
  • Contact us
  • Log In
No Result
View All Result
Neo Science Hub
No Result
View All Result
  • Home
  • e-Mag Archives
  • e-Learning
  • Categories
  • PhotoSynthesis
  • Subscribe Now
  • Contact us
  • Log In

When the Last Antibiotic Fails: ICMR Finds 91 Per Cent Carbapenem Resistance in a Common Hospital Pathogen

Naresh Nunna by Naresh Nunna
6 minutes ago
in Science News
0
Bar chart of decreasing bars beside a line-art antibiotic icon

ICMR’s 2025 surveillance report finds 91.1 per cent of Acinetobacter baumannii isolates resistant to carbapenems and fewer than one in ten E. coli isolates susceptible to ciprofloxacin. (Illustration)

The Indian Council of Medical Research’s antimicrobial resistance surveillance report for 2025 records resistance at levels that leave clinicians with very little to prescribe. Nine in ten Acinetobacter baumannii isolates resisted carbapenems, the class held in reserve for the most serious infections. Fewer than one in ten Escherichia coli isolates responded to ciprofloxacin. For the first time the network extended beyond large tertiary hospitals to 34 secondary-care hospitals, including 12 district hospitals — an important methodological step, because what happens outside metropolitan referral centres has until now been largely invisible.

Antimicrobial resistance is not a future risk in India. It is a present condition of its hospitals, measured annually, and the measurements are worsening. The Indian Council of Medical Research’s Antimicrobial Resistance Surveillance and Research Network, AMRSN, published its annual report for 2025 as World AMR Awareness Week opened on 18 November, and the figures describe a system in which the drugs of last resort are frequently no longer effective.

What the report covers

The network analysed 1,13,008 culture-positive samples from 30 large tertiary-care hospitals during 2025. Crucially, it also analysed 20,529 positive samples from 34 secondary-care hospitals, including 12 district hospitals — the first time the network has reported from that tier.

That extension deserves emphasis. Resistance data drawn only from large referral hospitals is systematically biased: those institutions receive the sickest patients, who have usually already been treated elsewhere, so their resistance rates are higher than the national picture and their case mix is unrepresentative. Extending surveillance to district hospitals begins to answer a question Indian policy has not been able to answer — what resistance looks like where most Indians actually receive care.

The organisms and the numbers

In the tertiary hospitals, four organisms dominated: Escherichia coli at 24.4 per cent of isolates, Klebsiella pneumoniae at 16.9 per cent, Pseudomonas aeruginosa at 12.2 per cent and Acinetobacter baumannii at 9.5 per cent. All four are Gram-negative bacteria, and all four are common causes of hospital-acquired pneumonia, bloodstream infection and urinary tract infection.

The susceptibility figures are where the report becomes alarming:

  • E. coli: 18.4 per cent of isolates susceptible to cefotaxime, 24.7 per cent to ceftazidime, and 9 per cent to ciprofloxacin. A drug effective in fewer than one in ten cases is not a usable empirical choice.
  • Klebsiella pneumoniae: only 36.5 to 40.4 per cent still susceptible to carbapenems, and lower in intensive-care samples.
  • Acinetobacter baumannii: 91.1 per cent carbapenem-resistant.
  • Staphylococcus aureus: 56.8 per cent methicillin-resistant, with some linezolid resistance also reported.

Carbapenems matter more than the other numbers. They are broad-spectrum beta-lactams held deliberately in reserve for serious Gram-negative infection, and for many such infections they are the last well-tolerated option. When fewer than two in five Klebsiella isolates respond and nine in ten Acinetobacter isolates do not, the clinician’s remaining choices are older, more toxic agents such as colistin, or combinations with thin evidence.

For enteric and diarrhoeal infections the figures are similarly stark. Ciprofloxacin susceptibility was 7.5 per cent in Shigella flexneri, 8.9 per cent in S. sonnei and 0.7 per cent in diarrhoeagenic E. coli; cefixime susceptibility in diarrhoeagenic E. coli was 4.6 per cent. Salmonella Typhi, the typhoid organism, still responds to azithromycin and ceftriaxone, but its ciprofloxacin susceptibility is described as extremely low. The practical message the report draws is that fluoroquinolones should not be used indiscriminately for diarrhoeal illness and that severe or persistent cases warrant laboratory testing.

The newborn data

The report’s separate analysis of neonates — infants up to 28 days — is the finding with the sharpest human edge. Klebsiella pneumoniae accounted for 25.1 per cent of bloodstream isolates in newborns, with Candida species and Acinetobacter baumannii also common, and susceptibility to third-generation cephalosporins was poor.

Neonatal sepsis is a condition in which hours matter. Treatment must begin before culture results are available, which means it must be based on what the local resistance pattern suggests will work. If a quarter of neonatal bloodstream infections are caused by an organism poorly susceptible to the standard empirical choice, then the standard choice is failing some of those infants before anyone knows it.

What the report recommends

The recommendations are unglamorous and largely about hospital practice: strengthen infection prevention and control, which means hand hygiene, sterilisation of instruments and cleaning of surfaces and equipment; make laboratory diagnostics reliable and available; guide treatment by susceptibility results rather than habit; protect carbapenems and other last-resort agents through disciplined prescribing; and build region-specific surveillance and guidelines, because resistance patterns differ between places.

There is a reason the emphasis falls on infection control rather than on new drugs. Resistant organisms in hospitals spread primarily by transmission between patients, via hands, instruments and surfaces. An infection prevented needs no antibiotic at all, which makes infection control the only intervention that reduces both resistance and its consequences simultaneously. It is also, in practice, the hardest to sustain, because it depends on thousands of repeated acts by overstretched staff rather than on a procurement decision.

Context, and the international echo

An earlier ICMR study, reported in September 2026, examined 26,213 confirmed Gram-negative infections across 20 hospitals between 2022 and 2025 and found 61.1 per cent carbapenem-resistant, with higher mortality where resistance was present — 31.2 per cent against 23.5 per cent for K. pneumoniae — and treatment costs one to two times higher. India launched its National Action Plan on Antimicrobial Resistance 2.0, covering 2025 to 2029, in November 2025.

The same week brought a comparable warning from Europe, where the European Centre for Disease Prevention and Control described the spread of carbapenem-resistant Enterobacterales and clinicians reported patients for whom no effective agent remained. This is not an Indian problem with an international footnote; it is a global problem on which India has unusually good surveillance data and unusually severe numbers.

Limitations

NSH was unable to locate the AMRSN 2025 report itself on icmr.gov.in. All the figures above come from a single news report of 18 November, corroborated only in general terms by a second outlet. A separate ICMR annual report for 2023 is publicly available and NSH consulted it for context, but it is a different document with different figures and the two should not be conflated. No ICMR official is quoted in the coverage, no year-on-year comparison with 2024 is given, and NSH found no ICMR press release. The figures should be checked against the report before republication.

– Rashmi M

Share this:

  • Share on X (Opens in new window) X
  • Share on LinkedIn (Opens in new window) LinkedIn
  • Share on Facebook (Opens in new window) Facebook
  • Share on WhatsApp (Opens in new window) WhatsApp
  • Share on Tumblr (Opens in new window) Tumblr
  • Share on Telegram (Opens in new window) Telegram
  • Email a link to a friend (Opens in new window) Email
Tags: AntibioticsAntimicrobialResistanceHealthSciencesHospitalInfectionICMRIndiaPublicHealth
Naresh Nunna

Naresh Nunna

Other Posts

Map of India's east coast with a stylised cyclone and its forecast track

Akvan Turns North and Drops a Category: IMD Now Expects a Severe Cyclone Between Narsapur and Puri, While Andhra’s Own Forecasters Expect Less

November 21, 2026
0
Two proportion bars divided into coloured segments

Antalya’s Last Forty-Eight Hours: Two Contradictory Paragraphs on Fossil Fuels, and India’s Line on the Carbon Budget

November 21, 2026
0

Disarm, Don’t Kill: CCMB Scientists Find Two Compounds That Stop a Deadly Fungus Turning Invasive

Eighty Per Cent of the Cost: Andhra Pradesh Raises the Stakes in India’s Chip-Subsidy Contest

Before the First Breath: UNEP and WHO Say Hormone-Disrupting Chemicals Reach Us in the Womb

The Morning Eye Closes: NASA Will Switch Off Terra After 27 Years of Watching the Planet

A Status Lost: Measles Is Endemic Again in the United States, Mexico and Bolivia

The Earthshot Comes to Mumbai: An Indian Electric Three-Wheeler Maker Wins £1 Million for Cleaner City Air

Please login to join discussion

Subscribe to Us

Latest Articles

Cross-section of a human eye with the optic nerve head highlighted

FDA Orders Eye-Risk Warnings on All GLP-1 Drugs, From Ozempic to Mounjaro

November 12, 2026
11

Delhi’s Diwali, Measured: Firecrackers Drove 71% of Fine Particles, Lead Hit 20 Times the Limit, and the Worst Readings Went Missing

Global Carbon Budget 2026: The World’s Fossil Emissions Dip, India’s Rise 4.4%, and the 1.5 °C Budget Is Nearly Spent

A New Kind of Blood Thinner: FDA Approves Asundexian to Prevent Repeat Strokes

Andhra Pradesh Opens the Door to Small Nuclear Reactors, Robots and Giga-Scale AI Data Centres — With the Details Still to Come

“Off the Charts”: WMO Tells COP31 That 2026 Is Among the Hottest Years on Record as a Record El Niño Builds

  • Advertise
  • Terms and Conditions
  • Privacy Policy
  • Refund Policy
  • Contact
For Feedback : Email Us

Copyrights © 2025 Neo Science Hub

No Result
View All Result
  • Home
  • e-Mag Archives
  • e-Learning
  • Categories
    • Healthcare & Medicine
    • Pharmaceutical & Chemical
    • Automobiles
    • Blogs
      • Anil Trigunayat
      • BOOKmarked
      • Chadha’s Corner
      • Cyber Gyan
      • Raul Over
      • Taste of Tradition
      • Vantage
    • Business Hub
    • Engineering
    • Innovations
    • Life Sciences
    • Space Technology
  • PhotoSynthesis
  • Subscribe Now
  • Contact us
  • Log In

Copyrights © 2025 Neo Science Hub

Welcome Back!

Login to your account below

Forgotten Password? Sign Up

Create New Account!

Fill the forms below to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist